Suraksha Diagnostic Limited — Important, 27-03-2025: General Updates

Suraksha Diagnostic Limited has announced a board meeting outcome where the Board approved a strategic investment not exceeding ₹5.19 crore in Fetomat Wellness Private Limited, aiming for a 63% stake, making it a subsidiary. This acquisition involves subscribing to new equity shares and purchasing from current shareholders, enhancing Suraksha's offerings in fetal medicine and women’s health. Fetomat reported a turnover of approximately ₹4.11 crore for the last fiscal year, indicating growth potential. This investment is likely to strengthen Suraksha's market position, offering a positive outlook for investor sentiment, given the synergies in healthcare services.